Display options
Cite
Yan T, Greene M, Chang E, et al. Impact of Atypical Antipsychotics as Adjunctive Therapy on Psychiatric Cost and Utilization in Patients with Major Depressive Disorder. Clinicoecon Outcomes Res. 2020;12:81-89doi: 10.2147/CEOR.S231824.
Yan, T., Greene, M., Chang, E., Houle, C. R., Tarbox, M. H., & Broder, M. S. (2020). Impact of Atypical Antipsychotics as Adjunctive Therapy on Psychiatric Cost and Utilization in Patients with Major Depressive Disorder. ClinicoEconomics and outcomes research : CEOR, 1281-89. https://doi.org/10.2147/CEOR.S231824
Yan, Tingjian, et al. "Impact of Atypical Antipsychotics as Adjunctive Therapy on Psychiatric Cost and Utilization in Patients with Major Depressive Disorder." ClinicoEconomics and outcomes research : CEOR vol. 12 (2020): 81-89. doi: https://doi.org/10.2147/CEOR.S231824
Yan T, Greene M, Chang E, Houle CR, Tarbox MH, Broder MS. Impact of Atypical Antipsychotics as Adjunctive Therapy on Psychiatric Cost and Utilization in Patients with Major Depressive Disorder. Clinicoecon Outcomes Res. 2020 Feb 07;12:81-89. doi: 10.2147/CEOR.S231824. eCollection 2020. PMID: 32104020; PMCID: PMC7012250.
Copy Download .nbib Format: NLM
Share it on

Clinicoecon Outcomes Res. 2020 Feb 07;12:81-89. doi: 10.2147/CEOR.S231824. eCollection 2020.

Impact of Atypical Antipsychotics as Adjunctive Therapy on Psychiatric Cost and Utilization in Patients with Major Depressive Disorder.

ClinicoEconomics and outcomes research : CEOR

Tingjian Yan, Mallik Greene, Eunice Chang, Christy R Houle, Marian H Tarbox, Michael S Broder

Affiliations

  1. Partnership for Health Analytic Research, LLC, Beverly Hills, CA 90212, USA.
  2. Otsuka Pharmaceutical Development & Commercialization, Inc, Princeton, NJ, 08540, USA.
  3. Lundbeck, Deerfield, IL 60015, USA.

PMID: 32104020 PMCID: PMC7012250 DOI: 10.2147/CEOR.S231824

Abstract

INTRODUCTION: Patients with major depressive disorder (MDD) incur high costs, despite established treatment options. Adding an atypical antipsychotic (AAP) to antidepressant therapy has shown to reduce depressive symptoms in MDD, but it remains unclear with which adjunctive AAP to initiate. As economic burden is one factor that can influence treatment selection, this study's objective was to evaluate the impact of adjunctive AAP choice on psychiatric costs and healthcare utilization in MDD.

MATERIALS AND METHODS: This retrospective cohort study analyzed de-identified data from: (1) IBM

RESULTS: The final study sample consisted of 10,325 patients (7657 aripiprazole, 1219 brexpiprazole, 827 lurasidone, 622 quetiapine). Using brexpiprazole as reference, lurasidone and quetiapine users had $1662 and $3894 higher psychiatric costs, respectively. Psychiatric costs were not statistically significantly different between aripiprazole and brexpiprazole (p>0.05). Quetiapine users had $15,159 (p<0.001) higher psychiatric hospitalization costs among those hospitalized, and higher odds of psychiatric hospitalization [2.11 (1.46-3.04); p<0.001] compared to brexpiprazole users. No statistically significant differences observed in psychiatric hospitalization risk comparing aripiprazole and lurasidone with brexpiprazole (p>0.05).

CONCLUSION: In MDD, brexpiprazole users had significantly lower psychiatric costs than lurasidone and quetiapine users, and significantly lower psychiatric hospitalization risk than quetiapine users. Adjunctive AAP choice may impact subsequent healthcare costs and utilization in MDD.

© 2020 Yan et al.

Keywords: adjunctive therapy; atypical antipsychotics; healthcare utilization; major depressive disorder; psychiatric cost

Conflict of interest statement

Dr Tingjian Yan, Dr Eunice Chang, Ms Marian H Tarbox, and Dr Michael S Broder are employees of Partnership for Health Analytic Research, LLC, which was paid by Otsuka Pharmaceutical Development & Comm

References

  1. Int J Neuropsychopharmacol. 2017 Jan 1;20(1):22-30 - PubMed
  2. J Am Coll Cardiol. 2017 Jan 24;69(3):345-357 - PubMed
  3. J Clin Epidemiol. 1992 Jun;45(6):613-9 - PubMed
  4. Int Clin Psychopharmacol. 2018 Nov;33(6):312-321 - PubMed
  5. Annu Rev Public Health. 2018 Apr 1;39:489-505 - PubMed
  6. Ann Pharmacother. 2013 Jul-Aug;47(7-8):933-45 - PubMed
  7. PLoS Med. 2013;10(3):e1001403 - PubMed
  8. Clinicoecon Outcomes Res. 2013;5:49-57 - PubMed
  9. CNS Drugs. 2013 May;27 Suppl 1:S29-37 - PubMed
  10. J Clin Psychiatry. 2016 Mar;77(3):371-8 - PubMed
  11. BMC Psychiatry. 2017 Jun 19;17(1):222 - PubMed
  12. J Chronic Dis. 1987;40(5):373-83 - PubMed
  13. P T. 2016 Jul;41(7):418-22 - PubMed
  14. Am J Manag Care. 2007 Nov;13(4 Suppl):S92-7 - PubMed
  15. J Med Econ. 2018 Sep;21(9):888-901 - PubMed
  16. Adv Ther. 2015 May;32(5):429-44 - PubMed
  17. J Psychiatr Pract. 2008 Jan;14(1):34-44 - PubMed
  18. J Clin Psychiatry. 2015 Feb;76(2):155-62 - PubMed
  19. Am J Psychiatry. 2016 Apr 1;173(4):400-7 - PubMed
  20. J Affect Disord. 2017 Jan 01;207:54-62 - PubMed
  21. Braz J Med Biol Res. 2014 Jul;47(7):605-16 - PubMed
  22. Clinicoecon Outcomes Res. 2019 Dec 04;11:741-755 - PubMed
  23. Clin Ther. 2019 Feb;41(2):221-232 - PubMed
  24. Cochrane Database Syst Rev. 2010 Dec 08;(12):CD008121 - PubMed

Publication Types